Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study

1. Tabernero, J.
2. Yoshino, T.
3. Cohn, A.L.
4. Obermannova, R.
5. Bodoky, G.
6. Garcia-Carbonero, R.
7. Ciuleanu, T.-E.
8. Portnoy, D.C.
9. Van Cutsem, E.
10. Grothey, A.
11. Prausová, J.
12. Garcia-Alfonso, P.
13. Yamazaki, K.
14. Clingan, P.R.
15. Lonardi, S.
16. Kim, T.W.
17. Simms, L.
18. Chang, S.-C.
19. Nasroulah, F.